

A randomised controlled study of N-Acetylcysteine in liver transplantation

Submission date 12/09/2003	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 07/04/2011	Condition category Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Christopher Watson

Contact details
Honorary Consultant Surgeon
University Department of Surgery
Box 202
Addenbrooke's Hospital
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 336980
cjew2@cam.ac.uk

Additional identifiers

Protocol serial number
N0544103857

Study information

Scientific Title

Study objectives

N-Acetylcysteine in liver transplantation

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Surgery: Liver transplant

Interventions

Patients undergoing liver transplantation will be randomly allocated to the N-Acetylcysteine group or a control group (no treatment).

Treatment will commence during the liver transplant and continue for 5 days post-operatively. Blood tests and liver biopsies will be taken during the study for analysis.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

N-Acetylcysteine

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

01/09/2007

Reason abandoned (if study stopped)

Lack of staff/facilities/resources

Eligibility

Key inclusion criteria

Added May 2008:

Adult patients (≥ 18 years) undergoing liver transplant

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

Added May 2008:

Allergy to n-acetyl cysteine

Date of first enrolment

06/09/2001

Date of final enrolment

01/09/2007

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Honorary Consultant Surgeon

Cambridge

United Kingdom

CB2 2QQ

Sponsor information**Organisation**

Department of Health (UK)

Funder(s)

Funder type

Government

Funder Name

Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes